Eli Lilly and Company | Mega-cap | Healthcare
$775.35
-2.49%
| Eli Lilly and Stock Comparison:
Eli Lilly and vs Johnson & JohnsonEli Lilly and vs AbbVieEli Lilly and vs Merck & CoEli Lilly and vs AmgenEli Lilly and vs Gilead SciencesEli Lilly and vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 45.0B
Gross Profit 36.6B 81.31%
Operating Income 17.5B 38.86%
Net Income 10.6B 23.51%
EPS (Diluted) $11.71

Balance Sheet Metrics

Total Assets 78.7B
Total Liabilities 64.4B
Shareholders Equity 14.3B
Debt to Equity 4.52

Cash Flow Metrics

Operating Cash Flow 12.3B
Free Cash Flow 414.3M

Revenue & Profitability Trend

Eli Lilly and Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 45.0B 34.1B 28.5B 28.3B 24.5B
Cost of Goods Sold 8.4B 7.1B 6.6B 7.3B 5.5B
Gross Profit 36.6B 27.0B 21.9B 21.0B 19.1B
Operating Expenses 19.1B 16.3B 13.3B 13.1B 12.0B
Operating Income 17.5B 10.8B 8.7B 7.9B 7.1B
Pre-tax Income 12.7B 6.6B 6.8B 6.2B 7.2B
Income Tax 2.1B 1.3B 561.6M 573.8M 1.0B
Net Income 10.6B 5.2B 6.2B 5.6B 6.2B
EPS (Diluted) $11.71 $5.80 $6.57 $5.85 $6.47

Income Statement Trend

Eli Lilly and Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 32.7B 25.7B 18.0B 18.5B 17.5B
Non-Current Assets 46.0B 38.3B 31.5B 30.4B 29.2B
Total Assets 78.7B 64.0B 49.5B 48.8B 46.6B
Liabilities
Current Liabilities 28.4B 27.3B 17.1B 15.1B 12.5B
Non-Current Liabilities 36.1B 25.8B 21.6B 24.6B 28.3B
Total Liabilities 64.4B 53.1B 38.7B 39.7B 40.8B
Equity
Total Shareholders Equity 14.3B 10.9B 10.8B 9.2B 5.8B

Balance Sheet Composition

Eli Lilly and Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 10.6B 5.2B 6.2B 5.6B 6.2B
Operating Cash Flow 12.3B 6.1B 7.3B 7.4B 7.6B
Investing Activities
Capital Expenditures -5.1B -3.4B -1.9B -1.3B -1.4B
Investing Cash Flow -6.6B -4.8B -2.7B -2.4B -1.6B
Financing Activities
Dividends Paid -4.7B -4.1B -3.5B -3.1B -2.7B
Financing Cash Flow 1.2B 3.5B -5.4B -4.1B -3.1B
Free Cash Flow 414.3M -3.2B 4.6B 5.4B 4.5B

Cash Flow Trend

Eli Lilly and Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 62.76
Forward P/E 34.01
Price to Book 46.33
Price to Sales 14.12
PEG Ratio 34.01

Profitability Ratios

Profit Margin 22.67%
Operating Margin 42.49%
Return on Equity 77.28%
Return on Assets 16.45%

Financial Health

Current Ratio 1.37
Debt to Equity 243.61
Beta 0.39

Per Share Data

EPS (TTM) $12.28
Book Value per Share $16.64
Revenue per Share $54.44

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
lly 691.8B 62.76 46.33 77.28% 22.67% 243.61
Johnson & Johnson 364.1B 16.83 4.66 29.45% 24.42% 66.90
AbbVie 324.6B 78.87 228.56 88.40% 7.31% 4,789.60
Merck & Co 198.5B 11.49 4.12 39.29% 27.27% 71.99
Amgen 146.5B 24.84 23.60 105.67% 17.39% 924.46
Gilead Sciences 132.1B 22.31 6.90 32.65% 20.76% 130.79

Financial data is updated regularly. All figures are in the company's reporting currency.